<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176020</url>
  </required_header>
  <id_info>
    <org_study_id>2005-003234-18</org_study_id>
    <secondary_id>K115</secondary_id>
    <nct_id>NCT00176020</nct_id>
  </id_info>
  <brief_title>Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled, Single-Center, 2 Treatment, 3-Way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment,&#xD;
      3--way crossover. Subjects will be randomly allocated to a treatment sequence - AAB, ABA or&#xD;
      BAA. The two treatments will be:&#xD;
&#xD;
        -  Treatment A: 500 mg nicotinic acid (Niacor(R))&#xD;
&#xD;
        -  Treatment B: Niacor(R) Placebo&#xD;
&#xD;
      Each trial period will last one day, there will be a wash-out period of at least 2 days&#xD;
      between each trial period. Five to seven days after study day 1 of trial period 3 there will&#xD;
      be a final safety examination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>18</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotinic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good state of health physically and mentally&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any other investigational product in the last 60 days before the day of&#xD;
             randomization into the study&#xD;
&#xD;
          -  Regular use of medication in the last 60 days before the day of randomization into the&#xD;
             study except of oral contraceptives in female participants&#xD;
&#xD;
          -  Treatment in the 60 days before the day of randomization into the study with any drug&#xD;
             known to have a well-defined potential for toxicity to a major organ, or any substance&#xD;
             which is known to induce or inhibit hepatic drug metabolism (including general&#xD;
             anesthetics)&#xD;
&#xD;
          -  Any drug intake (including over-the-counter remedies) in the 2 weeks before the day of&#xD;
             randomization into the study, unless the investigator considers a drug intake to be&#xD;
             clinically irrelevant for the purpose of this study&#xD;
&#xD;
          -  Any acute or chronic illness or clinically relevant findings in the pre-study&#xD;
             examination&#xD;
&#xD;
          -  Presence, history or sequelae of gastrointestinal (e.g. peptic ulcer), liver or kidney&#xD;
             disease, or any other condition known to interfere with the absorption, distribution,&#xD;
             metabolism or excretion of drugs&#xD;
&#xD;
          -  History of hypersensitivity to the investigational product&#xD;
&#xD;
          -  History or presence of abnormalities of the vascular bed&#xD;
&#xD;
          -  History or presence of a dermatologic disease or skin lesions, particular in the area&#xD;
             chosen for flush measurement&#xD;
&#xD;
          -  History of allergy or hypersensitivity to other drugs or to food constituents&#xD;
&#xD;
          -  History of other allergic diseases or hypersensitivity, unless the investigator&#xD;
             considers it to be clinically irrelevant for the purpose of this study&#xD;
&#xD;
          -  Blood donation of &gt; 400 ml in the 60 days before the day of randomization into the&#xD;
             study&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Positive result in urine screen for drugs of abuse or in alcohol breath test&#xD;
&#xD;
          -  Known or suspected to be drug-dependent, including consumption of &gt; 30 g alcohol per&#xD;
             day&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Subject is the investigator or any sub-investigator, research assistant, pharmacist,&#xD;
             study coordinator, other staff or relative thereof directly involved in the conduct of&#xD;
             the protocol&#xD;
&#xD;
          -  Mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study&#xD;
&#xD;
          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Mikus, MD Bsc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Internal Medicine VI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte Tubach, R:N:</last_name>
    <email>brigitte.tubach@med.uni-heidelberg.de</email>
  </overall_contact>
  <verification_date>August 2005</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>March 14, 2006</last_update_submitted>
  <last_update_submitted_qc>March 14, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2006</last_update_posted>
  <keyword>nicotinic acid</keyword>
  <keyword>flush symptom</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

